neobavaisoflavone and Asthma

neobavaisoflavone has been researched along with Asthma* in 1 studies

Other Studies

1 other study(ies) available for neobavaisoflavone and Asthma

ArticleYear
Neobavaisoflavone inhibits allergic inflammatory responses by suppressing mast cell activation.
    International immunopharmacology, 2022, Volume: 110

    Neobavaisoflavone (NBIF), a monomolecular compound extracted from Psoralea corylifolia (Leguminosae), is commonly used in traditional Chinese medicine for multiple purposes. NBIF is known to exert anti-fungal and anti-tumor effects, and promote bone formation. Whether NBIF exhibits anti-allergic effects by regulating mast cell activation remains unclear. Therefore, we designed this study to investigate the anti-allergic effects of NBIF on IgE/Ag-induced mouse bone marrow-derived mast cells and ovalbumin-induced asthma, and the passive systemic anaphylaxis (PSA) reaction in mice. Our results showed that NBIF suppresses the production of leukotriene C4, prostaglandin D2 and inflammatory cytokines, and decreases the degranulation of BMMCs stimulated by IgE/Ag. A thorough investigation ascertained that NBIF suppresses the phosphorylation of mitogen-activated protein kinases, and represses the nuclear factor-κB-related signaling pathway. In addition, the oral administration of NBIF in mice inhibited the IgE-induced PSA reaction in a dose-dependent manner. Overall, we provide new insights into how NBIF regulates the IgE/Ag-mediated signaling pathways. Moreover, our investigation promotes the potential use of NBIF in treating allergy and asthma.

    Topics: Anaphylaxis; Animals; Anti-Allergic Agents; Asthma; Cell Degranulation; Hypersensitivity; Immunoglobulin E; Isoflavones; Mast Cells; Mice; Mice, Inbred BALB C

2022